434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)

Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants

Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336 · see citing works

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00605-7 · Cited by 320 · see citing works

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

Ryan, M. B., Coker, O., Sorokin, A., Fella, K., Barnes, H., Wong, E., Kanikarla, P., Gao, F., Zhang, Y., Zhou, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110993 · Cited by 177 · see citing works

Drugging KRAS: Current perspectives and state-of-art review

Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164 · see citing works

Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0405 · Cited by 144 · see citing works

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C. A., Albrecht, C., Alpar, D., Arnhof, H., Bergner, O., Bosch, K., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00800-6 · Cited by 76 · see citing works

Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer

Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 63 · see citing works

KRAS: A Druggable Target in Colon Cancer Patients

Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 55 · see citing works

Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer

Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 41 · see citing works

Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

Ji, J., Wang, C., & Fakih, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s340392 · Cited by 39 · see citing works

Prognostic and predictive molecular biomarkers in colorectal cancer

Zhang, J., Zhu, H., Liu, W., Miao, J., Mao, Y., & Li, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1532924 · Cited by 24 · see citing works

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern

Akhave, N. S., Biter, A. B., & Hong, D. S. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0356 · Cited by 17 · see citing works

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69943-7 · Cited by 13 · see citing works

The shadow of cancer therapeutic resistance: Unveiling the role of S-palmitoylation

Yang, X., Xu, M., Deng, Z., & Xu, B. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101264 · Cited by 13 · see citing works

Application of histology-agnostic treatments in metastatic colorectal cancer

Bianchi, A. S., Agostara, A. G., Patelli, G., Mauri, G., Pizzutilo, E. G., & Siena, S. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.05.013 · Cited by 12 · see citing works

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Ghosh, S., Fan, F., Powell, R. T., Roszik, J., Park, Y. S., STEPHAN, C. C., Sebastian, M. M., Tan, L., Sorokin, A. V., Lorenzi, P. L., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0110 · Cited by 10 · see citing works

AZD4625 is a Potent and Selective Inhibitor of KRASG12C

Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9 · see citing works

New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer

Damato, A., Rotolo, M., Caputo, F., Borghi, E., Iachetta, F., & Pinto, C. (2022) · Life · doi:10.3390/life12081137 · Cited by 5 · see citing works

ESMO 2021—highlights in colorectal cancer

Weiß, L. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00808-7 · Cited by 5 · see citing works

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective

Koessler, T., Alsina, M., Arnold, D., Ben‐Aharon, I., Collienne, M., Lutz, M. P., Neuzillet, C., Obermannova, R. L., Peeters, M., Sclafani, F., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100392 · Cited by 4 · see citing works

Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer

Kavgacı, G., Dızdar, Ö., & Yalçın, Ş. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001587 · Cited by 5 · see citing works

LUMAKRAS® (sotorasib)

Tamayo, N. A., Wurz, R. P., & Lanman, B. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00001-2 · Cited by 1 · see citing works

Molecular profiling in colorectal cancer

Piringer, G. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00833-6 · Cited by 1 · see citing works

Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancersPreprint

Misale, S., Yaeger, R. D., Mezzadra, R., Sinopoli, J. C., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1236956/v1 · Cited by 1 · see citing works

Development of a new therapeutic approach based on peptide nanoparticles delivering CRISPR-Cas9 for the specific targeting of KRAS mutations

Gonzalez, V. G. (2023) · doi:10.70675/f8c09968z97c4z4635za591z74bf90b6fe70

45MO Sotorasib in Combination with Panitumumab in Refractory KRAS G12C-Mutated Colorectal Cancer: Safety and Efficacy for Phase Ib Full Expansion Cohort

Kuboki, Y., Yaeger, R., Fakih, M., Strickler, J. H., Masuishi, T., Kim, E. J.-H., Bestvina, C. M., Langer, C. J., Krauss, J. C., Puri, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.077 · Cited by 20 · see citing works

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.

Hong, D. S., Kuboki, Y., Strickler, J. H., Fakih, M., Houssiau, H., Price, T. J., Élez, E., Siena, S., Chan, E., Hippenmeyer, J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.3513 · Cited by 19 · see citing works

315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Kuboki, Y., Yaeger, R., Fakih, M., Strickler, J. H., Masuishi, T., Kim, E. J., Bestvina, C. M., Langer, C. J., Krauss, J. C., Puri, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.453 · Cited by 18 · see citing works

444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101)

Masuishi, T., Kuboki, Y., Fakih, M., Strickler, J. H., Furqan, M., Kim, E. J., Cardona, P., Tran, Q., Chan, E., & Hong, D. S. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.1865 · Cited by 4 · see citing works

92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort

Masuishi, T., Strickler, J. H., Machiels, J.-P., Hong, D. S., Greil, R., Chan, E., Hippenmeyer, J., Saportas, Y., Cardona, P., Xia, C., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.227 · Cited by 2 · see citing works